Skip to main content
Premium Trial:

Request an Annual Quote

ArcticZymes, Tataa Ink Sales, Distribution Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian enzymes firm ArcticZymes and Swedish gene expression profiling company Tataa Biocenter today announced a mutual sales and distribution deal covering Europe.

The terms of the agreement calls for Tataa to sell ArcticZymes' heat-labile enzymes for use in contamination control through its sales channels. Tataa will also integrate ArcticZymes' products into its range of courses.

Additionally, ArcticZymes will launch two reference gene panels and the ValidPrime kits series from Tataa. The kits offer for the first time a "rational and economical tool" for determining DNA contamination level, the companies said.

Financial and other terms of the deal were not disclosed.

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.